



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/646,060	08/22/2003	Richard B. Murphy	016930-004530US	8810
20350	7590	10/03/2006		
TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			EXAMINER WHITEMAN, BRIAN A	
			ART UNIT	PAPER NUMBER
			1635	

DATE MAILED: 10/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/646,060

Applicant(s)

MURPHY, RICHARD B.

Examiner

Brian Whiteman

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 10 July 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 34 and 40-55 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 34, 40-55 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_.

### **DETAILED ACTION**

Claims 34 and 40-55 are pending.

Applicant's traversal, the cancellation of claims 1-33 and 35-39, the addition of claims 40-55, and the amendment to claim 34 in paper filed on 7/10/06 is acknowledged and considered by the examiner.

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 34 remain and claims 40-55 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims read on using a genus of targeted complexes having the formula: (delivery vehicle-CM) - TMI - (CM-targeting ligand); wherein delivery vehicle-CM is a delivery vehicle that displays on its surface a polypeptide that comprises a chelating moiety (CM), TMI is a transition metal ion, and CM-targeting ligand is a chelating moiety (CM) covalently linked to a targeting ligand that binds to the target cell *in vivo*. The delivery vehicle is an adenoviral vector. Thus, the claims are considered broad. The claims will therefore be evaluated based upon *in vivo* use of the targeted complex.

The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the application coupled with information known in the art without undue experimentation (*United States v. Teletronics, Inc.*, 8 USPQ2d 1217 (Fed. Cir. 1988)). Whether undue experimentation is required is not based upon a single factor, but rather a conclusion reached by many factors. These factors were outlined in *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and again in *In Re Wands* (see above).

Furthermore, and with respect to claims directed to an adenoviral vector useful for gene therapy and directed to any treatment of a mammal; the state of the art as exemplified by Anderson et al., *Nature*, Vol. 392, pp. 25-30, 1998, displays major consideration for any gene transfer or any DNA therapy protocol involve issues that include:

- 1) The type of vector and amount of DNA constructs to be administered, and
- 2) The route and time course of administration, the sites of administration, and successful uptake of the claimed agent at the target site;

In addition, all of these issues differ dramatically based on the specific vector used and the route of administration.

Anderson teaches that several major deficiencies still exist including poor delivery systems, both viral and non-viral (pp. 25-30). Therefore, at the time the application was filed, targeted delivery was considered unpredictable.

For additional reviews of the unpredictability of targeting a specific cell in vivo, see references 4-6 cited on the PTO-1449.

Applicant provides no working example of the claimed invention. Applicant contemplates delivering a diagnostic agent to a specific cell in vivo. However, the relevance of

Art Unit: 1635

this contemplation to practicing the claimed method is unclear at best because neither the applicant nor the prior art of record provide a correlation or nexus between the results contemplated by applicant with the results which the skilled artisan would reasonably expect to see *in vivo*.

The invention involved one of the most complex areas of medicine/molecular biology, delivering an agent to a targeted cell *in vivo*. The credentials of those skilled in the art are high (PhDs and M.D.s); however, if one looks at the almost unknown failure of said skilled artisan to reduce targeting a specific cell *in vivo*, their level of skill in actually practicing the claimed invention is low.

In conclusion, the specification and instant claims coupled with the art of record, at the invention was made, do not provide sufficient guidance and/or evidence to reasonably enable the skilled artisan to practice the claimed invention. Given that targeted delivery to a cell *in vivo* wherein an adenovirus is employed was unpredictable at the time the invention was made, and given the lack of sufficient guidance as to specifically targeting a cell using the targeted complex cited in the claims, one skilled in the art would have to engage in a large quantity of undue experimentation in order to practice the claimed invention based on the applicant's disclosure and the unpredictability of targeted delivery, based on the applicants' disclosure, and the unpredictability of targeted delivery *in vivo*.

Applicant's arguments filed 7/10/06 have been fully considered but they are not persuasive.

Applicant argues that the rejection appears to be based in part on the alleged difficulties of using any viral vector in the claimed method and amendment the claims to recited adenovirus should overcome the rejection.

Applicant's argument is not found persuasive because the rejection is based on the undue experimentation required to delivery the vehicle to a target cell in vivo. The instant specification provides no working of the claimed invention. Although it is acknowledged that a working example is not required to provide enablement for a claimed invention, in view of the In Re Wands Factors, the skilled artisan would require an undue amount of experimentation to practice the claimed method. See MPEP 2164.02.

It is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of an invention in order to constitute adequate enablement, e.g. Genentech Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1366, 42, USPQ2d 1001, 1005 (Fed. Cir. 1997).

Furthermore, the court in Enzo 188 F.3d at 1374, 52 USPQ2d at 1138 states:

It is well settled that patent applications are not required to disclose every species encompassed by their claims, even in an unpredictable art. However, there must be sufficient disclosure, either through illustrative examples or terminology, to teach those of ordinary skill how to make and use the invention as broadly as it is claimed.

In re Vaack, 947 F.2d 48, 496 & n.23. 30 USPQ2d 1438, 1445 & n.23 (Fed. Cir. 1991)(citation omitted). Here, however, the teachings set forth in the specification provide no more than a "plan" or "invitation" for those of skill in the art to experiment...; they do not provide sufficient guidance or specificity as to how to execute that plan. See Fiers v. Revel, 984 F.2d.1164, 1171, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993); In re Wright, 999 F.2d...[1557], 1562, 27 USPQ2d...[1510], 1514. [Footnote omitted].

On this record, it is apparent that the specification provides no more than a plan or invitation in view of the art of record exemplifying the unpredictability of targeting a specific cell in vivo, for those skilled in the art to undue experiment with different delivery vehicles so as to provide an a

Art Unit: 1635

method of delivering a diagnostic agent to a target cell in an organism as intended by the as-filed specification at the time the invention was made.

See also Genentech Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1366, 42, USPQ2d 1001, 1005

(Fed. Cir. 1997)

("Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable the public to understand and carry out the invention.")

In view of the art of record and the lack of guidance provided by the specification; the specification does not provide reasonable detail for what protocols are required for different target cells, and it would take one skilled in the art an undue amount of experimentation to reasonably extrapolate from the assertion in the specification to the claimed invention. Therefore, the as-filed specification is not enabled for the claimed invention.

### ***Response to Arguments***

Applicant's arguments, see page 7, filed 7/10/06, with respect to objection have been fully considered and are persuasive. The objection of claims 34-37 has been withdrawn because of the amendment to claim 34 and the deletion of claims 35-37.

Applicant's arguments, see page 8, filed 7/10/06, with respect to 112 second paragraph rejection have been fully considered and are persuasive. The rejection of claims 34-37 has been withdrawn because of the amendment to claim 34 and the deletion of claims 35-37.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian Whiteman whose telephone number is (571) 272-0764.

Art Unit: 1635

The examiner can normally be reached on Monday through Friday from 7:00 to 4:00 (Eastern Standard Time), with alternating Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras, SPE – Art Unit 1635, can be reached at (571) 272-4517.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Fax Center number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Brian Whiteman

BRIAN WHITEMAN  
PATENT EXAMINER  
P R